Navigation Links
Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Date:6/2/2008

Japan Submission Includes Clinical Data Demonstrating Superiority of XIENCE

V Compared to TAXUS(R) Drug Eluting Stent

TOKYO, June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced that it has submitted an application for Seizo Hanbai Shonin (Marketing Authorization License) to Japan's Ministry of Health, Labour and Welfare (MHLW)/ Pharmaceuticals and Medical Devices Agency (PMDA) to gain approval for its XIENCE(TM) V Everolimus Eluting Coronary Stent System to treat coronary artery disease. The Shonin application for XIENCE V consisted of safety and efficacy data from the SPIRIT III clinical trial, including data from a Japanese patient population. As previously reported, results from the SPIRIT III U.S. pivotal clinical trial demonstrated the superiority of XIENCE V over Boston Scientific's TAXUS(R) paclitaxel-eluting coronary stent system in the primary endpoint of in-segment late loss at eight months.

"Results of the SPIRIT III Japan Registry were very similar with those of the U.S. randomized clinical trial, which was the first head-to-head clinical trial to demonstrate the superiority of one drug eluting stent over another drug eluting stent," said Daniel Estay, divisional vice president, Abbott Vascular Asia Pacific and Japan. "XIENCE V represents an advancement in drug eluting stent science and reinforces Abbott's deep commitment to providing physicians and patients in Japan with leading technologies and products in cardiac and vascular care."

The XIENCE V stent utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation, and is built upon Abbott's MULTI-LINK VISION(R) Coronary Stent System, the world's market-leading b
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
2. Abbott to Present at Citi Investment Research Global Health Care Conference
3. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
4. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
5. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
6. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
7. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
8. Abbott Hosts Conference Call for First-Quarter Earnings
9. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
10. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
11. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 With a mere ... Charlie Crist made a brief fundraising stop at the ... Thursday. , Fresh from a debate last night with ... the stage for the first seven minutes because Crist ... governor described the incident in one word: "weird." , ...
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium organic ... to celebrate this month. October marks Italian Heritage Month – ... of Americans of Italian heritage and Italians in America. October ... its favorite Italian cocktails and encourages everyone to enjoy its ... it is only in a glass. , Punzoné continues ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... and increased weight in the middle school students reports that ... of food as motivation resulted in an increase in the ... and organizing fund raising programs with food as a sole ... two thirds of adults and on third of children population ...
... Evidence of brain enlargement has been discovered by magnetic ... suffer from autism, when in comparison to other normal ... ,Abnormalities in communication, repetitive and stereotyped behaviors, and ... The neuroanatomical basis for this condition is yet to ...
... Sexually Transmitted Infections in Africa (ICASA) aimed at combating ... the Continent’s scientists in Nigeria on 4 December 2005.// ... implementation of the projects and better utilization of funds. ... have been infected by the disease, which is representative ...
... vaccination against bird flu to all its poultry birds and wild ... to farmers and villagers about the importance of vaccination to poultry ... doubtful death of birds in their area as it is reported ... has reported two human deaths due to bird flu and is ...
... Washington it was reported that hormone injections (Leptin) taken twice daily ... weight. ,The research was headed by Dr Michael Rosenbaum ... // New York which shed light on the complex pathway that ... weight what is more difficult is to maintain the weight. ...
... University have found that increased levels of plasma lipoprotein ... increasing the risk of heart disease in these patients. ... the supporting tissue that surrounds the teeth. Previous studies ... diseases including diabetes and cardiovascular disease. The current study ...
Cached Medicine News:Health News:Leptin Injections Maintain Loss In Body Weight 2Health News:Severe Gum Disease Triples Heart Disease Risk 2
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014 /PRNewswire/ ... Neuropathy Foundation (HNF), both philanthropies, announced today the ... candidates for the treatment of the rare disease ... BioPontis Alliance announced its alliance model earlier this ... first demonstration of a collaborative model where researchers ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3